Luminex Corporation Announces the Release of xPONENT® 3.1 Software
25 February 2009 - 2:00AM
Business Wire
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in
multiplexed solutions, today announced the commercial release of
xPONENT� 3.1 data acquisition software. Launched for use on Luminex
100 and Luminex 200 systems, xPONENT 3.1 includes more than 65 new
features designed to benefit scientists and laboratory
professionals across research and clinical diagnostic markets in
simplifying laboratory workflow and increasing productivity.
Luminex simultaneously announced that it has added xPONENT 3.1 to
its FDA-cleared Luminex 100 and 200 systems for use in clinical
diagnostic applications.
�xPONENT 3.1 is an innovative and exciting software upgrade for
Luminex�s partners and customers, as it provides a range of new
tools to help scientists work more efficiently and effectively,�
said Patrick Balthrop, President and Chief Executive Officer of
Luminex. �Furthermore, adding the new software to our FDA-cleared
multiplexing system allows our partners and customers in the
diagnostics field to upgrade their laboratories.�
xPONENT 3.1 was developed with direct feedback from users across
a range of research and clinical diagnostic disciplines. The
software is being released together with repackaged system reagents
and a new Automated Maintenance Plate (AMP). These components
combine to enable the automation of daily system maintenance
operations and to increase walk-away time.
New features and enhancements of the xPONENT 3.1 software
product line include an intuitive navigation structure,
touch-screen capability, intra-well normalization function,
advanced data-analysis tools and an enhanced database and
underlying data management architecture.
For laboratories working under the FDA�s 21 CFR part 11
regulations, xPONENT software offers multilevel user management,
full audit trail electronic records and electronic signatures. The
software can be included in integrated systems interfaced with
Laboratory Information Systems (LIS/LIMS) and front-end automation
platforms. It has been designed to support both carboxylated and
magnetic bead applications.
xPONENT 3.1 will be sold on new Luminex systems and will be
available as an upgrade to the more than 5,800 existing Luminex 100
and 200 systems in the marketplace worldwide.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets
proprietary biological testing technologies with applications
throughout the diagnostic and life sciences industries. The
Company�s xMAP� multiplex solutions include an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics markets. The
Company�s xMAP Technology is sold worldwide and is already in use
in leading clinical laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on
Luminex Corporation or xMAP Technology can be obtained at
www.luminexcorp.com.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024